Nov 9, 2023 By Business Wire 8 min read

DUBLIN-(BUSINESS WIRE)-Nov 9, 2023-

The “Graves’ Disease – Pipeline Insight, 2023″ drug pipelines has been added to ResearchAndMarkets.com’s offering.

The “Graves’ Disease – Pipeline Insight, 2023” report offers comprehensive insights into the Graves’ Disease pipeline landscape, encompassing information on more than 8 companies and over 10 pipeline drugs.

It provides detailed profiles of these pipeline drugs, including their clinical and nonclinical stages of development. The report also evaluates these therapeutics based on product type, development stage, route of administration, and molecule type, while also highlighting any inactive pipeline products in this field.

The report delivers a thorough understanding of the current scenario and growth prospects within the Graves’ Disease indication. It furnishes an extensive overview of the Graves’ Disease pipeline landscape, including information on the disease itself and treatment guidelines.

The assessment section of the report includes a comprehensive commercial assessment of Graves’ Disease, as well as a clinical evaluation of the pipeline products currently in development.

It offers detailed descriptions of these drugs, covering their mechanisms of action, clinical studies, potential NDA approvals, and various product development activities such as technology used, collaborations, licensing agreements, mergers and acquisitions, funding, designations, and other pertinent product-related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Graves’ Disease R&D. The therapies under development are focused on novel approaches to treat/improve Graves’ Disease.

Graves’ Disease Emerging Drugs Chapters

This segment of the Graves’ Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Graves’ Disease Emerging Drugs

Batoclimab: Immunovant Sciences GmbH

Batoclimab (IMVT-1401) is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). The FcRn receptor facilitates IgG recycling. Batoclimab enhances the degradation of IgG by targeting FcRn and preventing endogenous IgG from binding. This increased catabolism of IgG may curtail the harmful immune response exhibited by auto-antibodies.

In nonclinical studies and in clinical trials conducted, batoclimab was observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases and, as a result, the company believes that this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered subcutaneous injection. The drug is currently being investigated in the Phase III stage of development for the treatment of Graves’ Disease.

Linsitinib: Sling Therapeutics

Linsitinib is an oral small molecule that works by inhibiting the validated IGF-1R target. Linsitinib has established a safety profile through the treatment of over 800 patients. It is also being investigated for the treatment of additional autoimmune and rare diseases. Currently, linsitinib is in a Phase IIb trial for thyroid eye disease (TED).

VRDN-001: Viridian Therapeutics

Viridian’s lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). In preclinical studies, VRDN-001 was shown to be a full antagonist of IGF-1R, with more complete receptor blockade than other anti-IGF-1R antibodies, including the approved TED therapy.

Data from the initial dose cohorts of the Phase 2 portion of the ongoing trial established clinical proof-of-concept for VRDN-001 in patients with active TED. Preliminary data from the ongoing trial showed treatment with VRDN-001 led to reductions in proptosis, clinical activity score (CAS), and diplopia resolution. VRDN-001 was generally safe and well tolerated in the trial.

The company initiated the THRIVE Phase III trial in patients with active TED to support global marketing registration. VRDN-001 is also being evaluated in Phase II trial cohorts in patients with chronic TED. Pending positive results, the company plans to start its THRIVE-2 Phase III trial in patients with chronic TED.

Key Questions Answered

• How many companies are developing Graves’ Disease drugs?
• How many Graves’ Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Graves’ Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Graves’ Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Graves’ Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Viridian Therapeutics
• Immunovant Sciences GmbH
• Apitope International NV
• Sling Therapeutics
• Novartis Pharmaceuticals

Key Products

• VRDN-001
• Batoclimab
• Linsitinib
• CFZ533
• K1-70

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Graves’ Disease Report Insights

• Graves’ Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Graves’ Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pxkwn2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com:https://www.businesswire.com/news/home/20231109645893/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2023.

PUB: 11/09/2023 06:27 AM/DISC: 11/09/2023 06:28 AM

http://www.businesswire.com/news/home/20231109645893/en